drugset / Trial / NCT04023630
DUAL Antithrombotic Therapy in Patients With AF and ACS
RandomizedParallel-groupOpen-labelTreatment
Summary
The study aims to show inferiority of rivaroxaban plus ticagrelor when compared to rivaroxaban plus clopidogrel in terms of safety. Safety will be determined by comparing the rates of death or ischemic event-including myocardial infarction, definite or probable stent thrombosis, stroke, or urgent revascularization.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2020-09-30
- Completion
- 2021-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | Oral |
| Subject | Ticagrelor | Small molecule | 90 mg | Oral |
| Background | Rivaroxaban | Other / unclassified | 15 mg | Oral |